53 results about "Plasma glucose level" patented technology

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

This invention describes a rapid immunochromatographic assay for measuring the ratio of glycated albumin to total albumin in saliva. Patients with diabetes have elevated levels of glucose in their blood that can react with plasma albumin to form glycated albumin. The amount of glycated albumin formed is directly correlated with the level of plasma glucose that the albumin has been exposed to over a period of time. Saliva albumin is derived from plasma albumin and therefore contains glycated and non-glycated albumin fractions that can be measured. The ratio of glycated albumin to total albumin in saliva will provide an indication of the average amount of protein glycation that occurred over the preceding 2-3 week period. The test is performed using a disposable strip that contains the testing reagents and the results are measured in a measuring instrument that automatically reads, calculates and displays the final result. The results of tests performed over a period of time are stored in the instrument's memory and presented in a numerical or graphical format so that the individual's glycated albumin level can be monitored over time.

This invention describes a rapid assay for measuring the ratio of glycated albumin to total albumin in blood. Patients with diabetes have elevated levels of glucose in their blood that can react with plasma albumin to form glycated albumin. The amount of glycated albumin formed is directly correlated with the level of plasma glucose that the albumin has been exposed to over a period of time. The ratio of glycated albumin to total albumin in blood will provide an indication of the average amount of protein glycation that occurred over the preceding 2-3 week period. The test is performed using a disposable strip or cassette that contains the testing reagents and the results are measured in a measuring instrument that automatically reads; calculates and displays the final result: The results of tests performed over a period of time are stored in the instrument's memory presented in a numerical or graphical format so that the individual's glycated albumin level can be monitored over time.

Disclosed herein are exendin singly modified with polyethylene glycole or a derivative thereof, a method for the preparation of the same, and uses thereof. Exendin modified at lysine (27) with polyethylene glycol shows biological activity similar to that of natural exendin, but is improved in half life. In addition, the modification position and the number of PEG or its derivative are restricted so as to minimize the side effects caused by a variety of combinations of such factors. The exendin is useful in the prevention and treatment of diseases caused by the over-secretion of insulin, or diseases caused due to a decrease in plasma glucose level, the inhibition of gastric or intestinal motility, the promotion of satiety, or the inhibition of food intake, especially diabetes, obesity and irritable colon syndrome.

The invention is a method of controlling an artificial pancreas. The method includes reading and recording a current plasma glucose level. The method includes computing glucose in beta cell if a current plasma glucose level is greater than a threshold value, and continuing the step of reading and recording a current plasma glucose level if a current plasma glucose level is less than a threshold value. The method includes calling ATP functions for interpolation. The method includes calculating a holding capacity. The method includes calculating a synthesized insulin amount. The method includes comparing amount of insulin with the holding capacity. The method includes releasing insulin if the amount of insulin is greater than the holding capacity, and not releasing insulin if the amount of insulin is less than the holding capacity.

The present invention addresses substituted cyanothiophene derivatives of the formula I:

as well as compositions containing such compounds and methods of treatment. The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose providing a treatment of diabetes.

The invention provides a method for generating a type II diabetes mellitus and/or Syndrome X model in pigs. A method of the invention comprises partially destructing pancreatic beta-cells in pigs. From these pigs, a pig is preferably selected that comprises a fasting plasma glucose level higher than 6 mmol/L. The invention further provides a pig according to the invention and uses thereof.

A method of treating or preventing diabetes or obesity that comprises administering an antioxidant-enriched composition produced by fermenting fruit extracts with the bacteria Serratia vaccinii. The antioxidant-enriched composition is capable of decreasing plasma glucose levels, increasing circulating adiponectin levels and decreasing hyperphagia in a subject.

The invention discloses application of salvia miltiorrhiza extracts in preparing a protein tyrosine phosphatase 1B inhibitor and a drug for preventing and/or treating type 2 diabetes. The salvia miltiorrhiza extracts salvianolic acid C, salvianolic acid A, danshinolic acid C or salvianolic acid A methyl ester can significantly inhibit the activity of protein tyrosine phosphatase 1B, further increase the glucose uptake rate, reduce the plasma glucose levels and prevent and/or treat the type 2 diabetes. The salvianolic acid C, the salvianolic acid A, the danshinolic acid C or the salvianolic acid A methyl ester are used as active ingredients to make a pharmaceutical preparation which can be used as the protein tyrosine phosphatase 1B inhibitor to prevent and/or treat the type 2 diabetes.

The present invention belongs to the field of pharmaceutical industry and relates to a dry pharmaceutical composition comprising Canagliflozin, as well as to a process for preparing the same. Such dry pharmaceutical composition is useful as a medicament, especially for the normalization of plasma glucose levels.

The present invention discloses a novel anti-diabetic composition extracted from fenugreek seeds. The same comprises a furostanolic-saponin-rich fraction (>70%) with approximately 30% protodioscin as one of the bioactive components. Pre-clinical studies in rats indicated significant glucose lowering effect of the fraction (31.5%) as compared to control after two weeks of oral treatment. Clinical studies in human volunteers indicated suitability of a dosage form of 500 mg given once or twice daily as anti-diabetic agent either alone or in combination with standard, synthetic anti-diabetic drugs such as metformin and glipizide in controlling plasma glucose levels.

The invention discloses functions and application of TNF (tumor necrosis factor) receptor associated factor 5 (TRAF5) in treatment of fatty liver and type 2 diabetes mellitus. Studies on a TRAF 5 gene by a high-fat diet (HFD) induced model discover that both the body weight and fasting plasma glucose level of an HFD bred TRAF gene knock-out mouse are lower than those of a WT mouse; glucose tolerance tests by intraperitoneal injection discover that the glucose tolerance of the TRAF5 gene knock-out mouse is remarkably reinforced; results of on liver gross appearance, liver weight, liver/body weight ratio and lipid component pathological staining indicate that the TRAF5-KO mouse fatty liver lesion in the HFD group is remarkably improved, the lipid accumulation is remarkably reduced, and the TRAF5 gene knock-out has the effects of remarkably improving fatty acid and type-II diabetes mellitus. Against the effects, the TRAF5 gene knock-out can be used as a medicinal target for screening and treating fatty liver and/or type-II diabetes mellitus, and the inhibitor of the TRAF5 gene knock-out can be used for preparing medicaments for treating fatty liver and/or type-II diabetes mellitus.

The invention relates to the technical field of health caring, in particular to a preparation method of oral liquid for treating diabetes. Firstly, ligularia intermedia and Chinese aralis are cleanlycleaned; polysaccharide substances and total saponin substances in the ligularia intermedia and the Chinese aralis can effectively prevent the continuous rise of the plasma glucose level; the ultra microstructure of the kidney is maintained; the substrate membrane thickening is avoided, so that the filtration function of the glomerulus is normal; through the joint fermentation of lactobacilli andsaccharomycetes, ingredients for maintaining the blood glucose are converted into beneficial substances capable of being easily digested and absorbed by the human body; the molecular weight of the effective medicine ingredients is reduced; new microbial metabolism secondary products and other probiotics are generated; under the condition of co-existence of the saccharomycetes and the lactobacilli,lactic acid is converted into lactose; the lactose is decomposed to be converted into galactose; the synergistic effect is achieved; the content of ingredients, with the blood glucose reduction effect, in the fermented ligularia intermedia and Chinese aralis is improved; the diabetes is better treated in an auxiliary way.

The invention discloses an intranasal insulin preparation and a preparation method thereof. The intranasal insulin preparation is commonly formed by cell-penetrating peptide dissolved in a liquid-phase carrier and insulin. The cell-penetrating peptide is polypeptide molecule containing specific sequences of amino acids, so that the insulin can be promoted to enter into a human body through a mucosa of a nasal cavity, and the plasma glucose level is regulated. The preparation method of the preparation comprises the main preparing steps of: dissolving the therapeutic dose of insulin by hydrochloric acid; diluting to be required concentration by the liquid-phase carrier; regulating pH to be neutral by sodium hydroxide; mixing with a specific volume of cell-penetrating peptide; filtering and degerming; and storing at low temperature. The preparation can be applied to the surface of the mucosa of the nasal cavity of a person or an animal through an intranasal feeder. Compared with a subcutaneous insulin infusion preparation with the same dosage, according to the intranasal insulin preparation, the relative drug absorption rate is about 80 percent, and the bioavailability reaches more than 60 percent. The cell-penetrating peptide and the insulin have no stimulation on the mucosa of the nasal cavity, the amino acids can be degraded in vivo, the half-life period is short, and the safety is high.

The invention discloses application of vaccarin in preparation of medicines for resisting a diabetic lipid metabolism disorder, belonging to the field of traditional Chinese medicine preparation. The vaccarin is applied to development of the medicines for resisting the diabetic lipid metabolism disorder to obtain a better method for treating diabetes. After mice with type 2 diabetes are subjected to intraperitoneal injection of the vaccarin, the fasting plasma glucose level is significantly reduced; the levels of serum triglyceride (TG), total cholesterol (TCH) and low-density lipoprotein cholesterol (LDL-C) of the mice with type 2 diabetes are improved; the diabetic lipid metabolism disorder can be effectively changed by the vaccarin; the vaccarin is a traditional Chinese medicine for treating the diabetes, and can be developed as a novel medicine, a healthcare product and a nutrition for treating the diabetes; and novel path and means are provided for treatment of the diabetic lipid metabolism disorder.